Skip to main content

H. Lundbeck A/S (LUN.CO)

Nasdaq Copenhagen Healthcare Drug Manufacturers - Specialty & GenericView data quality →
64.9Fair

ValueMarkers Composite Index

Top 93%#3,071 of 44,707
Slightly Undervalued

12% below intrinsic value ($31)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.43
Low Risk
Altman
1.56
Distress
DCF Value
$31
Undervalued
ROIC
10.0%
Adequate
P/E
12.5
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

H. Lundbeck A/S (LUN.CO) — VMCI valuation read

Across 120 indicators, H. Lundbeck A/S (LUN.CO) lands at VMCI 65/100. The Healthcare sector median is 50, so the 15-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on LUN.CO in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, LUN.CO trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -1.1x leaves covenant headroom for LUN.CO on the trailing balance sheet.

LUN.CO rose 3.4% over the trailing 7 days, with a -10.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in LUN.CO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.